ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ベンジダミン

Benzydamine

HCID 12555
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
642-72-8
標準SMILES
CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12
InChIKey
CNBGNNVCVSKAQZ-UHFFFAOYSA-N
分子式
C19H23N3O
平均分子量
309.4 g/mol
単同位体質量
309.18411237

概要

Benzydamine is a member of the class of indazoles carrying benzyl and 3-(dimethylamino)propyl groups at positions 1 and 3 respectively. A locally-acting nonsteroidal anti-inflammatory drug that also exhibits local anaesthetic and analgesic properties. It has a role as a central nervous system stimulant, a non-steroidal anti-inflammatory drug, an analgesic, a hallucinogen and a local anaesthetic. It is an aromatic ether, a member of indazoles and a tertiary amino compound. It is a conjugate base of a benzydamine(1+).

名称と識別子

優先名称
Benzydamine
IUPAC
3-(1-benzylindazol-3-yl)oxy-N,N-dimethylpropan-1-amine
現地名
ベンジダミン
英語名
Benzydamine
分子式
C19H23N3O
分子量
309.41

名称と別名

BENZYDAMINE642-72-8BenzidamineBenzindamineBencidaminaBenzydaminumBenzidaminaApo-Benzydamine1-Benzyl-3-(3-(dimethylamino)propoxy)-1H-indazole1-Benzyl-3-[3-(dimethylamino)propoxy]-1H-indazole4O21U048EF{3-[(1-benzyl-1H-indazol-3-yl)oxy]propyl}dimethylamine
名称をさらに表示
ベンジンダミンN,N-ジメチル-3-[(1-ベンジル-1H-インダゾール-3-イル)オキシ]プロパン-1-アミンベンジダミン1-ベンジル-3-(3-ジメチルアミノプロポキシ)-1H-インダゾール1-ベンジル-3-[3-(ジメチルアミノ)プロポキシ]-1H-インダゾールN,N-ジメチル-3-[[1-(フェニルメチル)-1H-インダゾール-3-イル]オキシ]-1-プロパンアミン{3-[(1-ベンジル-1H-インダゾール-3-イル)オキシ]プロピル}ジメチルアミンBenzyaMineAURORA KA-7514Benzydamine (>90%)Benzydamine USP/EP/BPBenzydamine, 10 mM in DMSOBenzydamine (base and/or unspecified salts)INDAZOLE,1-BENZYL-3-(3-(DIMETHYLAMINO)PROPOXY)-
1-Propanamine, N,N-dimethyl-3-((1-(phenylmethyl)-1H-indazol-3-yl)oxy)-DTXSID7047859CHEBI:945631-Propanamine, N,N-dimethyl-3-[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]-(3-((1-benzyl-1H-indazol-3-yl)oxy)propyl)dimethylamineNovo BenzydaminePMS Benzydamineratio Benzydamine

物性

構造計算による物性補完中

XLogP
3.9
極性表面積
30.3 Ų
水素結合供与体数
0
水素結合受容体数
3
回転可能結合数
7
重原子数
23
形式電荷
0
複雑度
344

実験および物理化学的性質

Drugs · 3 件

Synthetic Cannabinoids

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

SolubilityMiscible
Human DrugsPharmaceuticals
Melting Point320°F
Dissociation Constants9.27
Collision Cross Section174.24 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
167 · 167-170 °C
沸点
0.05 · bp0.05 160°
比重(密度)
1.1106 · 1.1106 (rough estimate)
屈折率
1.59 · 1.5900 (estimate)
貯蔵温度
Refrigerator
溶解性
クロロホルム(少量)、メタノール(少量)
外見
油
酸解離定数(Pka)
9.25 · 9.25±0.28(Predicted)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

危険有害性情報

Other Safety InformationIMAP assessments - 1-Propanamine, N,N-dimethyl-3-[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

安全データ

wgk
WGK 3
毒性
LD50 orl-rat: 9500 mg/kg ARZNAD 22,711,72
Hazard Classifications
Acute Tox. 4 Oral
ストレージクラス
11 - Combustible Solids

化学と産業

薬理情報

ATC Code · 6 件

M - Musculo-skeletal system

A - Alimentary tract and metabolism

R - Respiratory system

G - Genito urinary system and sex hormones

M - Musculo-skeletal system

QA - Alimentary tract and metabolism

Protein BindingBenzydamine exhibits < 20% plasma protein binding after oral administration.
Pharmacodynamics · 1 件

Benzydamine is a non-steroidal anti-inflammatory drug (NSAID) designed to elicit local anesthetic and analgesic effects mainly for the mouth and throat. It specifically acts on the local mechanisms of inflammation such as pain, oedema, or granuloma. Typically applied topically, the drug demonstrates anti-inflammatory activity reducing oedema as well as exudate and granuloma formation. Moreover, benzydamine exhibits analgesic properties and local anaesthetic activity if pain is caused by an inflammatory condition. Benzydamine can be absorbed into the oral mucosa and intact skin. Once absorbed in the local area of pain or inflammation, benzydamine binds selectively to local inflamed tissues, usually allowing it to act with few adverse systemic effects. On average a period of 2 to 4 hours is necessary for the substance to reach peak plasma concentration. Benzydamine can be synthesized with the reaction of the N-benzyl derivative from methyl anthranilate with nitrous acid to give N-nitoso derivative. This is next reduced by sodium thiosulfate to give transient hydrazine. This hydrazine can then undergo spontaneous internal hydrazide formation. Treating this resultant enolate with 3-chloro-1-dimethylamkino propane ultimately yields benzydamine.

Mechanism of Action · 1 件

Despite being categorized as a non-steroidal anti-inflammatory drug (NSAID), benzydamine demonstrates various mechanisms of action that differ from those of traditional aspirin-like NSAIDs. In particular, benzydamine predominantly acts by inhibiting the synthesis of pro inflammatory cytokines like tumour necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β) without largely affecting other pro inflammatory cytokines (ie. such as IL-6 and IL-8) or anti-inflammatory cytokines (ie. like IL-10 or IL-1 receptor antagonist). Moreover, benzydamine is largely a weak inhibitor of prostaglandin synthesis as it has been shown to effectively inhibit cyclooxygenase (COX) and lipoxygenase enzyme activity only at concentrations of 1mM or greater. Considering most contemporary usages of benzydamine are topical applications that are generally not well absorbed through the skin and/or non-specialized mucosae, benzydamine does not often achieve the kind of absorption or blood concentrations necessary to cause any extraneous distant systemic effects or COX inhibition, allowing it to localize its action. Additionally, it is also hypothesized that benzydamine is capable of inhibiting the oxidative burst of neutrophils and membrane stabilization. These actions are exhibited by the substance’s ability to inhibit the release of granules from neutrophils and to stabilize lysosomes. Furthermore, benzydamine is capable of a local anaesthetic effect that may be related to its capability for inhibiting the release of inflammatory mediators like substance P and calcitonin gene related peptide from sensory nerve endings. Since substance P is capable of causing the release of histamine from mast cells, benzydamine’s prevention of substance P release further contributes to an anti-inflammatory effect. Benzydamine also demonstrates a non-specific antibacterial activity against various bacterial strains that are resistant to broad-spectrum antibiotics such as ampicillin, chloramphenicol, and tetracycline at concentrations of about 3 mmol/L. Combinatorial use of benzydamine and other antibiotics like tetracycline and chloramphenicol are also synergistic against antibiotic resistant strains of *Staphylococcus aureus* and *Pseudomonas aeruginosa*.

関連反応

1 件
反応記録を作成
HRID 1658823 の反応式
HRID 1658823生成物として反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
642-72-8
PubChem CID
12555
DTXSID
DTXSID7047859
ChEMBL
CHEMBL12610
ChEBI
CHEBI:94563
UNII
4O21U048EF
EC Number
211-388-8
Nikkaji
J7.060B
色
オレンジ
InChI
1S/C19H23N3O.ClH/c1-21(2)13-8-14-23-19-17-11-6-7-12-18(17)22(20-19)15-16-9-4-3-5-10-16;/h3-7,9-12H,8,13-15H2,1-2H3;1H
InChIKey
HNNIWKQLJSNAEQ-UHFFFAOYSA-N
SMILES
[Cl-].[N+H](CCCOc1n[n](c3c1cccc3)Cc2ccccc2)(C)C
CAS データベース
642 · 642-72-8(CAS DataBase Reference)
NISTの化学物質情報
1 · 1-Propanamine, n,n-dimethyl-3-[[1-(phenylmethyl)-1h-indazol-3-yl]oxy]-(642-72-8)
Biological Half-LifeApproximately 13 h after oral administration, with a terminal half life of about 7.7 h.
Metabolism/Metabolites · 1 件

Benzydamine is primarily metabolized by oxidation, dealkylation, and conjugation into hydroxy, dealkylated, and N-oxide metabolites. In general, however, when used at the recommended doses the levels at which benzydamine is absorbed or exposed into the body are usually not sufficient to produce systemic pharmacological effects [L

MeSH Pharmacological ClassificationSubstances that reduce or suppress INFLAMMATION.
Absorption, Distribution and Excretion · 4 件

Oral doses of benzydamine are well absorbed and plasma drug concentrations reach a peak fairly rapidly and then decline with a half-life of approximately 13 hours. When applied topically, although the local drug concentrations are relatively large, the systemic absorption of topically applied benzydamine is relatively low compared to oral doses. This low topical absorption contributes to a decreased potential for any systemic drug side-effects when benzydamine is administered in this way.

The relatively high lipid solubility of the weak base benzydamine is thought to be associated with considerable passive resorption within the renal tubule, which suggests that only approximately 5% of benzydamine is excreted unchanged in the urine. At the same time however, other studies have suggested that considerably larger amounts (50-65%) of the drug is excreted unchanged in urine. While several inactive oxidized metabolites of benzydamine are excreted in urine, the benzydamine N-oxide metabolite can remain in plasma and demonstrate a half-life that is longer than the parent benzydamine compound. Nevertheless, it is generally believed that excretion occurs mainly through urine and is mostly in the form of inactive metabolites or conjugation products.

The volume of distribution of benzydamine is 10 L.

Benzydamine demonstrateas a systemic clearance of 170 ml/min.

用途と製造

UsesUse (kg; approx.) in Germany (2009): >50
Use ClassificationPharmaceuticals
応用分野 · 2 件

説明Benzydamine is an analytical reference standard categorized as an analgesic. Benzydamine has been abused and is associated with hallucinations, muscle weakness, and excitability. This product is intended for research and forensic applications.

使用Analgesic; antipyretic; anti-inflammatory.

上流・下流製品情報

下流製品

塩酸ベンジダミン